Insulin Glargine - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026 - 2031)

According to Mordor Intelligence, the insulin glargine market size was valued at USD 2.62 billion in 2025 and estimated to grow from USD 2.78 billion in 2026 to reach USD 3.73 billion by 2031, at a CAGR of 6.05% during the forecast period (2026-2031).

This report is Segmented by Brand (Lantus, Basaglar, Toujeo, Soliqua/Suliqua, Glargine Biosimilars), Concentration (U100, U300), Indication (Type-1 Diabetes, Type-2 Diabetes), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Geography (North America, Europe, Asia-Pacific, and More). The Market Forecasts are Provided in Terms of Value (USD) and Volume (Units).

Global Insulin Glargine Market Trends and Insights

Rising Prevalence of Diabetes

Global diabetes prevalence has quadrupled since 1990 and now affects more than 500 million adults, with projections indicating 852 million cases by 2050. Type 2 diabetes comprises 96% of cases, and two-thirds of individuals initiating basal therapy start with glargine formulations. Incidence is surging in low- and middle-income countries where 90% of untreated patients reside, magnifying unmet need. Regional spikes are steepest in the Middle East and North Africa, while Brazil could see a 400% rise to 43 million cases by 2036. The expanding clinical and economic burden, estimated at USD 1,015 billion in 2024, is pushing payers toward cost-effective basal options, strengthening long-run demand for glargine biosimilars.

Emergence of Biosimilar Insulin Glargine

Three FDA-approved glargine biosimilars-two interchangeable-have re-shaped formulary negotiations and unlocked automatic substitution pathways in pharmacies. Biocon Biologics scaled up capac-ity while bilateral regulatory alignment between FDA and EMA reduced review times. Brazil streamlined approvals in 2024, enabling domestic programs that cut treatment expenditures by 55.9%. Multisource supply diminishes single-origin risks and lowers budget impact, although developers must still navigate patent thickets and meticulous quality audits.

High Cost of Insulin Therapy

Even after the Medicare cap, affordability gaps persist because 20% of beneficiaries lack Part D coverage and remain exposed to high out-of-pocket spending. US insulin prices still average nearly 10 times OECD levels. Globally, 19.5% of surveyed patients ration doses due to financial strain. Supply shocks compound the issue, illustrated by South Africa's 2024 pen shortages amid GLP-1 production swings. These cost and availability challenges cap near-term volume growth even as prevalence climbs.

Other drivers and restraints analyzed in the detailed report include:

1. Rapid Growth of e-pharmacy Channel Widening Home-care Access
2. Technological Advancements in Insulin Delivery
3. Complex Regulatory and Approval Pathways

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Lantus held 43.72% of 2025 revenue, anchoring the insulin glargine market through longstanding clinical trust and formulary placement. However, glargine biosimilars are leveraging interchangeability to capture switching prescriptions at an 8.25% CAGR. Basaglar, designated a follow-on biologic, exploits value-tier pricing, while Toujeo differentiates with U300 dosing. Soliqua/Suliqua combines glargine with lixisenatide to address multi-drug regimens. Second-generation biosimilars from Gan & Lee and Biomm are entering tender systems in Latin America, indicating accelerating commoditization. Originators respond by bundling devices, digital coaching, and co-pay assistance.

Physician surveys suggest confidence in biosimilar immunogenicity is rising, supported by post-marketing surveillance. Payers are mandating step-therapy that prioritizes lower-net-cost glargine biosimilars before covering originators, accelerating displacement. Nonetheless, clinical inertia favors brands with decades of safety records in vulnerable populations such as pregnant women. Marketing focus is therefore pivoting from molecule attributes to ecosystem value, including smart pen compatibility, digital titration support, and integrated glucose dashboards, tactics intended to protect share in a price-rationalizing landscape.

U100 products represented 70.85% of 2025 volume and remain the standard initiation strength worldwide. Familiar insulin-to-carbohydrate ratios and established dosing algorithms give clinicians confidence. However, U300 variants like Toujeo posted a 6.95% CAGR as reduced injection volume and flatter pharmacokinetic curves appealed to adherence-challenged cohorts. Clinical evidence shows lower nocturnal hypoglycemia and tighter fasting glucose ranges with U300 regimens.

Biosimilar developers are expanding portfolios to include both strengths, ensuring formulary parity with originators. Device manufacturers are updating cartridge specifications for dual-strength compatibility, reducing barriers to adoption. Cost differentials remain a restraint: U300 per-unit prices average 18% higher than U100, although lower volume requirements narrow the annual therapy gap. Patient education is critical because dosing confusion can lead to accidental under-treatment. Overall, concentration diversification underscores the ongoing evolution from molecule exclusivity toward holistic treatment experience.

Complete Report Scope:

• By Brand
  • Lantus
  • Basaglar
  • Toujeo
  • Soliqua / Suliqua
  • Glargine Biosimilars
• By Concentration
  • U100
  • U300
• By Indication
  • Type-1 Diabetes
  • Type-2 Diabetes
• By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America persisted as the largest contributor, with 44.98% market share in 2025, benefiting from high diabetes prevalence and premium pricing. The region's early adoption of biosimilar interchangeability promotes competitive discounts yet preserves substantial volume, while the USD 35 Medicare cap broadens access. Canada's universal-coverage legislation could further expand treated populations, particularly among low-income seniors. Innovation pipelines for smart delivery devices are concentrated in Silicon Valley and Minneapolis, reinforcing North America's leadership in integrated care ecosystems.

Europe displayed balanced market maturity and cost-containment rigor. Harmonized EMA guidelines implemented in 2024 shorten biosimilar review times, intensifying tender competition. Western countries such as Germany and France anchor revenue, while Central and Eastern Europe post higher growth from rising diagnosis rates and healthcare investment. Weekly icodec obtained EMA approval, signaling Europe's receptiveness to paradigm-shifting basal regimens. National procurement agencies increasingly bundle insulin with CGM subsidies, creating holistic tender parameters that reward suppliers offering device integration.

Asia-Pacific remains the fastest-growing (9.05%) territory through 2031, driven by explosive prevalence and policy interventions to alleviate affordability barriers. China's insulin tender program cut average glargine prices almost in half, boosting treated lives despite compressing unit margins. India unlocked needle-free delivery approvals and domestic manufacturing capabilities, widening therapeutic options. Southeast Asian e-pharmacy start-ups leverage smartphone ecosystems to deliver insulin within hours, bypassing under-resourced rural clinics. However, fragmented regulatory capacity and reimbursement heterogeneity slow cross-border launches, compelling suppliers to tailor country-specific market access strategies.

1. Sanofi
2. Eli Lilly and Company
3. Novo Nordisk
4. Biocon Biologics Inc.
5. Julphar (Gulf Pharmaceutical)
6. Gan & Lee Pharmaceuticals
7. Tonghua Dongbao Pharmaceutical Co., Ltd.
8. Wockhardt
9. Viatris (Mylan)
10. Boehringer Ingelheim

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support